MedTrace Logo

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

NCT01903356 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 724

Last updated 2018-12-21

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to monitor the safety profile of Trajenta Duo in Korean patients with type 2 diabetes mellitus (T2DM) in a routine clinical setting.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Trajenta duo

Linagliptin and Metformin

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-11
Primary Completion
2017-05-30
Completion
2017-06-10

Countries

  • South Korea

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01903356 on ClinicalTrials.gov